Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect information on the anti-tumor activity of the
combination doxorubicin, cisplatin, and 5-fluorouracil when given to patients with advanced
esophageal or gastric adenocarcinoma. We will also be collecting information about the side
effects and safety of this combination.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Massachusetts General Hospital